Dimensional Fund Advisors LP Boosts Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Dimensional Fund Advisors LP raised its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,810,770 shares of the medical equipment provider’s stock after purchasing an additional 154,447 shares during the period. Dimensional Fund Advisors LP owned 0.88% of Zimmer Biomet worth $196,523,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of ZBH. Janney Montgomery Scott LLC raised its position in shares of Zimmer Biomet by 21.6% in the fourth quarter. Janney Montgomery Scott LLC now owns 23,295 shares of the medical equipment provider’s stock valued at $2,835,000 after buying an additional 4,141 shares during the last quarter. Brown Advisory Inc. raised its position in shares of Zimmer Biomet by 2.4% in the fourth quarter. Brown Advisory Inc. now owns 16,799 shares of the medical equipment provider’s stock valued at $2,044,000 after buying an additional 396 shares during the last quarter. Coldstream Capital Management Inc. raised its position in shares of Zimmer Biomet by 6.4% in the fourth quarter. Coldstream Capital Management Inc. now owns 2,842 shares of the medical equipment provider’s stock valued at $346,000 after buying an additional 170 shares during the last quarter. D.A. Davidson & CO. raised its position in shares of Zimmer Biomet by 18.9% in the fourth quarter. D.A. Davidson & CO. now owns 12,465 shares of the medical equipment provider’s stock valued at $1,517,000 after buying an additional 1,984 shares during the last quarter. Finally, Corient Private Wealth LLC raised its position in shares of Zimmer Biomet by 5.3% in the fourth quarter. Corient Private Wealth LLC now owns 64,508 shares of the medical equipment provider’s stock valued at $7,851,000 after buying an additional 3,230 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Trading Up 0.0 %

NYSE ZBH opened at $106.32 on Friday. The firm has a 50 day simple moving average of $109.88 and a 200-day simple moving average of $115.65. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.63 and a current ratio of 1.29. Zimmer Biomet Holdings, Inc. has a one year low of $102.00 and a one year high of $133.90. The firm has a market cap of $21.65 billion, a price-to-earnings ratio of 23.01, a PEG ratio of 1.96 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, beating the consensus estimate of $1.99 by $0.02. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The business had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.94 billion. During the same quarter last year, the firm posted $1.82 earnings per share. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.02 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a $0.24 dividend. The ex-dividend date is Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.90%. Zimmer Biomet’s dividend payout ratio is currently 20.78%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ZBH. Oppenheimer reduced their target price on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday. Royal Bank of Canada cut their price objective on shares of Zimmer Biomet from $140.00 to $130.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. JPMorgan Chase & Co. cut their price objective on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a research report on Monday. Finally, Citigroup cut their price objective on shares of Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and a consensus target price of $125.17.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.